CDX2 and neoplasm: Nolte et al. demonstrated that the lower expression of CDX2 is inverselyrelated to the probability of certain factors, such as female gender, mucinoushistology, higher tumor pathological degree, higher pT staging, higher TNMclassification, lower disease-free survival (41% vs. 74% in positive CDX2 tumors)and lower overall survival in five years (33% vs. 59%), maintaining significanceeven in multivariate analyzes that excluded gender, tumor grade and clinicalstage.20